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The	Epstein-Barr	 virus	 (EBV)	 is	a	γ	herpes	virus	
that	infects	more	than	90%	of	the	human	population,	
although	the	majority	of	carriers	remain	asymptomatic.	
EBV	infection	is	associated	with	nasopharyngeal	car-
cinoma	(NPC)	and	Hodgkin	lymphoma	(HL)	[1].
The	WHO	classification	of	nasopharyngeal	carci-
nomas	distinguishes	two	major	types,	i.e.,	squamous	
cell	carcinoma	and	non-keratinizing	carcinoma,	 the	
latter	of	which	 includes	undifferentiated	carcinoma	
[2].Although	the	association	between	non-keratiniz-
ing	NPC	(particularly	of	the	undifferentiated	subtype)	
and	EBV	is	well	established,	NPC	oncogenesis	is	not	
a	simply	consequence	of	EBV	infection.
LMP-1	is	the	major	transforming	protein	of	EBV	and	
behaves	as	a	classical	oncogene.	LMP-1	is	an	integral	
membrane	protein	of	63	kDa,	and	can	be	subdivided	into	
three	domains	[3].	Its	two	distinct	functional	domains,	re-
ferred	to	as	C-terminal	activation	regions	1	and	2	(CTAR1	
and	CTAR2),	were	identified	because	of	their	ability	to	
activate	the	NF-κB	transcription	factor	pathway	[3].	
The	consequences	of	NF-κB	activation	are	numer-
ous	and	 include	 the	upregulation	of	anti-apoptotic	
gene	products	and	the	downregulation	of	cell	surface	
molecules	CD99.	In	NPC	cells,	LMP-1	induces	TRAF1	
expression	and	promotes	its	anti-apoptosis	activity	via	
the	NF-κB	signaling	pathway,	and	 thus	suppresses	
apoptosis	in	NPC	cells	[4].
CD99	is	a	strongly	sialoglycosylated	32	kDa	trans-
membrane	protein	 [5]	and	 is	 involved	 in	multifacto-
rial	cellular	events,	such	as	cell-cell	adhesion	during	
hematopoietic	cell	differentiation,	 the	apoptosis	of	
immature	thymocytes	and	neuronal	cells,	and	T-cell	
activation	 [6,	7].	NPC	and	Hodgkin	 lymphoma,	es-
pecially	Reed—Sternberg	cells	 (HRS)	share	several	
features	that	warrant	closer	examination	[8].	Kim	et	
al.	[9]	reported	that	HRS	cells	from	the	lymph	nodes	
of	HL	patients,	consistently	 lack	CD99	surface	ex-
pression.	Moreover,	 induced	LMP-1	expression	has	
been	demonstrated	to	directly	down-regulate	CD99	
in	B-cell	lines	at	the	transcriptional	level	via	the	NF-κB	
pathway	[10,	11].	This	finding	possibly	indicates	a	role	
for	the	LMP-1	induced	down	regulation	of	CD99	in	the	
generation	of	HRS-like	cells.	By	comparison,	little	is	
known	about	NPC	in	this	respect.	
The	aim	of	this	study	was	to	evaluate	the	expressions	
of	LMP-1	and	CD99	in	NPC	and	to	search	for	correla-
tions	between	these	expressions	and	tumor	growth.	
Materials and Methods
Patients and specimens.	A	 review	of	 the	H&E	
sections	of	40	patients	revealed	5	squamous	cell	car-
cinomas	(SCCs,	WHO	type	I),	20	non-keratinizing	car-
cinomas	(NKCs,	WHO	type	II),	and	15	undifferentiated	
carcinomas	(UCs,	WHO	type	III).	There	were	28	men	
and	12	women	(M	:	W=2.3	:	1),	and	patient	ages	ranged	
from	18	to	80	years	(mean	age	52.1	years).	NPC	di-
agnoses	were	confirmed	by	nasopharyngeal	biopsy	
at	 the	Department	of	Pathology,	Chonnam	National	
University	Hospital.	
Immunohistochemistry.	We	reviewed	the	hema-
toxylin	and	eosin	stained	slides	of	all	cases,	and	then	
selected	well	preserved	tissue	blocks	of	formalin-fixed,	
paraffin-embedded	samples.	The	immunohistochemi-
cal	analysis	included	monoclonal	antibody	for	LMP-1	
(DAKO,	clones	CS1-4,	CA,	USA:	dilution	1	:	400),	and	
CD99	(DAKO,	clones	12E7,	CA,	USA:	dilution	1	:	50).	Im-
munostaining	was	performed	using	the	routine	avidin-
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biotin	complex	(ABC)	method.	Briefly,	 representative	
paraffin	blocks	were	consecutively	sectioned	at	4µm	
and	 immunostainusing	a	Microprobe	 Immuno/DNA	
stainer	(Fisher	Scientific,	CA,	USA).	Sections	were	de-
paraffinized	in	xylene,	and	treated	with	0.3%	hydrogen	
peroxide	in	methanol	for	20	min	to	block	endogeneous	
peroxidase	activity.	For	LMP-1	and	CD99	immunostain-
ing,	sections	were	microwaved	 in	citrate-phosphate	
buffer	 (pH	6.0)	once,	and	 then	 incubated	with	anti-
bodies	at	 room-temperature	 for	1	h.	Anti-mouse	 im-
munoglobulin	G	(Sigma,	St.	Louis,	MO,	USA)	labeled	
with	biotin	was	used	as	a	secondary	antibody	to	detect	
primary	antibodies,	and	was	applied	by	incubation	for	
7	min	at	45	°C.	The	streptavidin-horseradish	peroxidase	
(Research	Genetics,	USA)	detection	system	used	 to	
visualize	capillary	channels,	by	 incubation	for	10	min	
at	45	°C.	After	drainage,	tissue	sections	were	reacted	
with	0.02%	diaminobenzidine	as	chromogen.	They	were	
then	counterstained	with	hematoxylin	and	mounted	in	
Universal	Mount	medium	(Research	Genetics,	USA).	
Cortical	thymus	tissue	was	used	as	positive	control	for	
CD99	staining.	Negative	controls	were	treated	similarly	
with	the	exception	of	primary	antibodies.		
Evaluation of immunohistochemical results.	All	
immunostained	slides	were	evaluated	 independently	
by	two	observers,	unaware	of	background	information,	
who	both	performed	evaluations	in	duplicate.	Appro-
priate	positive	and	negative	controls	were	prepared	in	
the	same	fashion.	Cytoplasmic	and/or	membranous	
staining	patterns	were	considered	positive	for	LMP-1.	
In	addition,	staining	in	the	Golgi	region	was	also	con-
sidered	positive	 for	LMP-1.	However,	 for	CD99	only	
membranous	staining	was	considered	positive.	Positive	
cell	 frequencies	were	evaluated	semi-quantitatively	
and	are	expressed	as	ratios	of	positive-stained	tumor	
cells	versus	the	total	tumor	cell	population.	They	were	
graded	from	0	to	+3	as	follows:	0	=	no	tumor	cells,	+1	=	
less	than	25%	tumor	cells,	+2	=	25%	to	50%	tumor	cells,	
and	+3	=	greater	than	50%	tumor	cells.	The	intensity	of	
staining	was	not	graded,	and	any	expression	of	LMP-1	
or	CD99	was	classified	as	positive.
Statistical analysis.	Statistical	analysis	was	per-
formed	using	SPSS	for	Windows,	version	10.0.1(SPSS	
Inc,	USA).	Results	were	statistically	evaluated	using	
the	Chi-square	 test	or	 the	Mann	Whitney-U	 test,	as	
modified	by	 Yates.	A	significance	 level	of	0.05	was	
used	for	all	statistical	tests.	
results
LMP-1 expression in NPC samples.	 In	order	 to	
identify	EBV-encoded	LMP-1	expression	in	NPC,	immu-
nostaining	for	LMP-1	was	performed	using	CS1-4	mono-
clonal	antibody	by	the	ABC	method.	A	dark	red	color	in	
the	cell	membrane	and	cytoplasm,	especially	 in	Golgi	
areas,	was	considered	as	a	positive	reaction.	LMP-1	was	
detected	only	in	tumor	cells;	infiltrating	lymphocytes	and	
stroma	were	unstained	(Fig.	1).	Moreover,	staining	inten-
sities	varied	from	cell	to	cell.	In	infiltrative	lymphocytes	
and	stroma,	LMP-1	was	completely	negative.	LMP-1	
expression	was	most	frequently	positive	in	WHO	type	III	
than	in	WHO	types	I	and	II,	and	this	type-associated	dif-
ference	was	significant	(p	=	0.034,	Table	1).
Fig. 1. Immunoreactivity	 for	LMP-1	 in	WHO	 type	 II	nasopha-
ryngeal	carcinoma.	Tumor	cells	exhibited	cytoplasm	and	Golgi	
apparatus	 focally	positive	 immunoreactivity.	The	 lymphocytes	
surrounding	the	tumor	cells	were	negative	(LMP-1,	X	400)	
Table 1. Distribution of LMP-1 expression in CD99 in lymphoid stroma/tu-
mor tissue according to the positive frequency
Localization of ex-
pression
LMP-1 p valueGrade Negative Positive Total
CD99 in lymphoid 
stroma
Negative 14  3 17
0.021Positive 14  9 23
Total 28 12 40
CD99 in epithelial 
tumor cells
Negative 26  9 35
0.294Positive  2  3 5
Total 28 12 40
Table 2. Distribution of LMP-1, CD99, and bcl-2 expression according to 
the histologic subtypes
Expression of the marker SCC NKC UC Total p value
LMP-1 0/5 5/20 7/15 12/40 0.034
CD99 in lymphoid stroma 0/5 11/20 11/15 23/40 0.440
CD99 in tumor 0/5  4/20 1/15 5/40 0.720
Notes: SCC — squamous cell carcinoma, WHO type I; NKC — non-keratinizing 
carcinoma, WHO type II; UC— undifferentiated carcinoma, WHO type III
cd99 expression in non-neoplastic nasopha-
ryngeal epithelium and nPc samples. Initially,	we	
evaluated	CD99	immunostaining	in	the	10	non-neoplastic	
nasopharyngeal	tissue	samples.	Some	of	these	samples	
were	obtained	 from	anterior	and	posterior	nasopha-
ryngeal	walls	 lined	by	stratified	squamous	epithelium,	
whereas	others	were	from	posterior	nares	or	the	roof	of	
the	posterior	wall	lined	with	ciliated	respiratory-type	co-
lumnar	epithelium.	All	samples	showed	CD99	expression	
along	nasopharyngeal	epithelial	cytoplasmic	borders	and	
in	some	lymphocytes	in	adjacent	areas	(Fig.	2).	
We	 then	evaluated	CD99	 immunostaining	 in	 the	
NPC	 samples,	where	CD99	was	more	 frequently	
expressed	in	surrounding	lymphoid	stroma	(23	of	40	
cases,	57.5%,	Fig.	3,	a,	Table	1)	than	in	epithelial	tu-
mor	cells	(5	of	40	cases,	12.5%,	Fig.	3,	b).	According	
to	WHO	types,	CD99	expression	in	lymphoid	stroma	
was	highest	in	WHO	type	III	(11	of	15	cases,	73.3%),	
and	was	completely	negative	in	WHO	type	I.	Moreover,	
the	staining	intensity	of	CD99	was	stronger	in	infiltrat-
ing	lymphocytes	and	stroma	than	in	tumor	cells.	No	
evident	correlation	was	observed	between	CD99	ex-
pression	in	stroma	or	tumor	cells	and	WHO	histologic	
classification	(Table	1).	However,	a	significant	positive	
correlation	was	observed	between	LMP-1	and	CD99	
expressions	in	lymphoid	stroma	(Pearson	correlation	
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coefficient	=	0.298,	p	=	0.021,	Table	2).	And,	in	patients	
with	positive	CD99	expression	in	epithelial	tumor	cells	
(5	of	the	40	cases),	LMP-1	was	negative	in	2	cases	and	
positive	in	3	cases,	whereas	in	patients	with	positive	
LMP-1	expression,	CD99	was	negative	in	9	of	12	cases	
(75.0%),	and	positive	in	3	of	12	cases	(25.5%).
Fig. 2. CD99	expression	in	non-neoplastic	nasopharyngeal	mu-
cosa.	All	cases	showed	CD99	expression	along	the	cytoplasmic	
borders	of	nasopharyngeal	epithelium	and	in	some	lymphocytes	
and	vascular	endothelial	cells	in	adjacent	areas
Fig. 3, a. Strong	CD99	immunostaining	in	WHO	type	III	naso-
pharyngeal	carcinoma.	This	pattern	is	similar	to	that	shown	by	
Ewing’s	sarcoma	and	primitive	neuroectodermal	tumor,	which	
also	show	membranous	accentuation	(CD99,	X		400)	
Fig. 3, b. Immunoreactivity	for	CD99	in	WHO	type	II	nasopharyn-
geal	carcinoma.	Tumor	cells	exhibited	negative	immunoreactivity,	
but	lymphocytes	surrounding	tumor	nests	were	strongly	positive	
(CD99,	×	400)
discussion
LMP-1	has	a	significant	effect	on	epithelial	 cell	
growth,	and	it	inhibits	the	differentiation	and	induces	
the	morphologic	transformation	of	some	cell	lines.	In	
this	study,	 in	order	 to	 identify	EBV-encoded	LMP-1	
expression	 in	NPC,	 immunostaining	of	 LMP-1	was	
performed	using	CS1-4	monoclonal	antibody	by	the	
ABC	method.	Of	 the	40	NPC	samples,	12	 (30.0%)	
showed	LMP-1	expression	confined	to	epithelial	tumor	
cells,	which	is	consistent	with	the	observation	that	viral	
DNA	is	detectable	in	malignant	epithelial	cells	rather	
than	 in	 the	abundant	 infiltrating	 lymphoid	cells	[12].	
LMP-1	has	been	detected	 in	 less	 than	50%	of NPC 
using	several	different	monoclonal	antibodies	[13,	14].	
However,	these	antibodies	did	not	recognize	all	forms	
of	LMP-1,	thus	the	reported	rate	of	LMP	detection	may	
represent	an	underestimation	[15].	Moreover,	it	is	pos-
sible	that	in	some	tumors	LMP-1	is	expressed	at	below	
the	level	of	detection	or	that	as	a	cancer	progresses	
the	expression	of	viral	protein	 is	no	 longer	 required	
as	other	genetic	changes	substitute	for	the	effects	of	
viral	proteins	[15].	
Kim	et	al.[9]	reported	that	HRS	cells	from	the	lymph	
nodes	of	HL	patients	consistently	lack	of	CD99	surface	
expression,	and	enhanced	LMP-1	expression	has	been	
shown	to	directly	down-regulate	CD99	in	B	cell	lines	
at	the	transcriptional	level	via	the	NF-κB	pathway.	In	
contrast,	 in	 the	present	study,	LMP-1	was	 found	 to	
be	positive	in	3	of	5	NPC	samples	expressing	CD99.	
In	terms	of	LMP-1	immunopositivity,	of	the	12	LMP-1	
positive	NPC	samples,	CD99	was	negative	in	9	cases	
(75.0%)	and	positive	in	3	(25.0%).	Our	findings,	and	
those	of	previous	reports	[9],	indicate	that	LMP-1	may	
induce	the	down-regulation	of	CD99	and	play	an	im-
portant	role	in	nasopharyngeal	carcinogenesis.	In	view	
of	the	finding	that	CD99-independent	LMP-1	induced	
pathways	generate	H-RS	cells	in	a	synergistic	way	[16],	
our	finding	of	LMP-1+CD99+	NPC	cells	indicates	the	
need	for	further	studies	to	elucidate	the	role	of	CD99	
in	NPC	carcinogenesis.	
Infiltrating	lymphocytes	and	lymphoid	stroma	are	
characteristic	histopathologic	features	of	WHO	type	III	
NPC.	Lymphoid	stroma	is	predominantly	composed	of	
T	cells,	and	CD4	and	CD8	expressing	cells	in	variable	
proportions	[17].	In	the	present	study,	a	considerable	
number	of	surrounding	lymphocytes	showed	strong	
reactivity	 for	CD99,	and	a	 significant	positive	cor-
relation	was	observed	between	LMP-1	expression	in	
tumor	cells	and	CD99	expression	in	lymphoid	stroma	
(Pearson	correlation	coefficient	=	0.298,	p	=	0.021,	
Table	2).	CD99	is	present	on	all	human	T-	cells,	but	has	
no	clear	biologic	function	[5,	18].	Studies	on	mature	
peripheral	T	cells	have	shown	that	co-ligation	of	CD99	
and	CD3	may	enhance	the	expression	of	CD25,	CD69,	
and	CD40	ligand,	induce	T-cell	proliferation,	and	also	
promote	the	production	of	TNF-α	and	IFN-γ	[7].	These	
findings	suggest	that	CD99	may	contribute	to	T-cell	
activation	in	NPC	microenvironment	and	promote	com-
munication	between	tumor	cells	and	tumor-infiltrating	
T	lymphocytes.	
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ВзаимосВязь между экспрессией cd99 и lMP-1 
В карциноме носоглотки
Цель: изучить роль экспрессии латентного мембранного белка-1 (LMP-1) EBV и CD99 при развитии карциномы носоглотки 
(КНГ). Материалы и методы: в соответствии с классификацией ВОЗ 40 образцов КНГ были отнесены к типам I, II, III. 
Иммуногистохимический анализ проводили с использованием моноклональных антител против LMP-1 и CD99. Уровень 
экспрессии CD99 также был определен в 10 образцах нетрансформированного эпителия носоглотки. Результаты: экспрессия 
белка LMP-1 была выявлена в 12 из 40 образцов КНГ (30%) только в эпителиальных клетках опухоли. В КНГ I типа все 
образцы были негативными по экспрессии LMP-1, а в КНГ III типа была обнаружена самая высокая степень  экспрессии. 
Интересно, что экспрессия CD99 была выявлена во всех контрольных образцах эпителия носоглотки по краю цитоплазмы. 
Ее также наблюдали в опухолевых клетках (в 12,5 образцов КНГ) и в окружающей лимфоидной строме (57,5% образцов 
КНГ), но не выявляли в КНГ І типа. Среди 12 LMP-1 позитивных образцов было выявлено 9 CD99 негативных (75,%) и 
3 — CD99 позитивных (25,5%). Также наблюдались статистически значимые различия между экспрессией LMP-1 и CD99 
в лимфоидной строме. Выводы:LMP-1 индуцирует подавление каскада CD99, выполняющего важную роль в образовании 
опухолей носоглотки. Экспрессия CD99 в лимфоидной строме может регулировать иммунную реакцию на КНГ.
Ключевые слова: вирус Эпштейна—Барр, латентный мембранный белок-1, CD99, карцинома носоглотки, лимфома 
Ходжкина.
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In	conclusion,	our	results	suggest	that	LMP-1	induc-
es	the	down-regulation	of	CD99,	and	that	this	might	be	
an	important	step	in	nasopharyngeal	carcinogenesis,	as	
shown	in	the	HRS	synthesis	in	HL.	Moreover,	our	find-
ings	show	that	CD99	expression	in	lymphoid	stroma	is	
influenced	by	the	presence	of	LMP-1.
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